University of California

NIH funds seven international centers of excellence for Malaria research

Monday, April 24, 2017

The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, announced approximately $9 million in first-year funding, subject to availability, for seven malaria research centers around the world. The seven-year awards continue NIAID’s 2010 program that created the International Centers of Excellence for Malaria Research (ICEMRs) in regions where malaria is endemic. The awards fund three new and four existing centers that work in 14 countries in Africa, Asia and Latin America.

[Read More]

CRISPR/Cas9 U.S. patent board decision appealed

Friday, April 14, 2017

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics announced that The Regents of the University of California, the University of Vienna and Dr. Emmanuelle Charpentier (collectively UC), co-owners of foundational intellectual property relating to CRISPR/Cas9 genome engineering, have appealed to the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit) the decision by the Patent Trial and Appeal Board (PTAB) to terminate the interference between certain CRISPR/Cas9 patent claims owned by UC and patents and patent applications owned by the Broad Institute, Harvard University and the Massachusetts Institute of Technology (collectively Broad).

[Read More]

BioMed Realty, UCSD to develop global center for oncology research

Tuesday, April 11, 2017

BioMed Realty, a Blackstone Real Estate company, and the University of California San Diego announced a new development known as the Center for Novel Therapeutics. The project will be home to university and local research organizations focused on finding critical treatments and potential cures for cancer and other chronic diseases. This new building will be centered in the university’s Science Research Park near Moores Cancer Center at UC San Diego Health.

[Read More]

Biogen appoints Anirvan Ghosh SVP, Research and Early Development

Friday, March 17, 2017

Biogen appointed Anirvan Ghosh, Ph.D., as senior vice president, Research and Early Development (RED). Dr. Ghosh will lead Biogen’s RED organization in the discovery and development of drug candidates from idea through proof of concept. He will report to Michael Ehlers, M.D., Ph.D., executive vice president, Head of Research and Development. Dr. Ghosh will begin his service at Biogen in April.

[Read More]

GSK’s real world study exemplifies trial design of the future

Monday, March 6, 2017

Using a novel trial design, GlaxoSmithKline (GSK) has conducted a study in Salford, U.K., using real-world data in patients with chronic obstructive pulmonary disease (COPD). The study used an electronic data-monitoring system to notify physicians immediately of any adverse events. The phase IIIb, open-label, randomized controlled trial (RCT) of Relvar lasted four years and enrolled almost any patient with COPD who wanted to participate, without the limitations on age and health status commonly placed on medication trials. Indeed, over one-half of the patients in Salford with COPD were recruited into the trial, which included 2,800 patients across 80 general practices.

[Read More]

Meet the newest ethical and legal challenge of obtaining and using data via the internet: The dark web

Wednesday, March 1, 2017

Are you afraid of the dark? What thoughts come to mind when you hear the word “dark”? Scary? Hidden? Sinister? Mysterious? Shadowy? The opposite of dark, of course, is “light” — and this signifies transparency, full disclosure, openness, and clarity. It is in this context that research professionals increasingly are using what is called the “dark web” to collect and use data for studies that are looking at activities that are often, but not always, illegal. What makes the dark web both intriguing and worrisome for researchers is not the kind of information it includes but rather the methods used to obtain the data (neither the usual search engines nor by hacking passwords).

[Read More]